Literature DB >> 24526358

Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT.

Sarah Wulfert1, Clemens Kratochwil, Peter L Choyke, Ali Afshar-Oromieh, Walter Mier, Hans-Ulrich Kauczor, Jens-Peter Schenk, Uwe Haberkorn, Frederik L Giesel.   

Abstract

PURPOSE: The purpose of this study is to investigate the utility of contrast-enhanced magnetic resonance imaging (CE-MRI), diffusion-weighted MRI (DW-MRI), and (68)Ga-DOTATOC positron emission tomography/computer tomography ((68)Ga-DOTATOC PET/CT) in the assessment of response to loco-regional peptide receptor radiotherapy (PRRT) with (90)Y-/(177)Lu-DOTATOC in patients with hepatic metastases from gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). PROCEDURES: CE-MRI, DW-MRI, and (68)Ga-DOTATOC-PET/CT images were acquired before and 3 months after one to two cycles of intra-arterial (90)Y-/(177)Lu-DOTATOC therapy in 14 patients (nine female, five male; mean age, 54 ± 9 years; range, 41-69 years) with hepatic metastases from GEP-NET. A total of 38 liver metastases were defined as target lesions for which the longest diameter, mean apparent diffusion coefficient (ADCmean) and maximum standardized uptake value (SUVmax) were assessed. Based on changes in size on follow-up imaging, target lesions were classified as responding (RL) or nonresponding (NRL). Relative changes in tumor size, ADCmean, and SUVmax were compared between the two subgroups.
RESULTS: A total of 27 responding and 11 nonresponding lesions were successfully evaluated. Mean ADCmean increased significantly in RL (p = 0.011) as well as NRL (p = 0.025). A significant correlation was found between baseline ADCmean and both the percent ADCmean change (p = 0.033) and decrease in lesion size after therapy (diameter p = 0.006; volume p = 0.002). SUVmax of RL declined significantly by 24.1 % (p = 0.014) and remained nearly unchanged in NRL. The change of SUVmax correlated significantly with the pretreatment SUVmax (p < 0.001) and the change in lesion diameter (p = 0.009). NRL with an ADCmean change >0.31 × 10(-3) mm(2)/s on first follow-up imaging showed a decrease in size in the long-term course.
CONCLUSION: These results suggest that both DW-MRI and DOTATOC-PET imaging provide potential biomarkers for early assessment of treatment and stratification of therapy response, but that DW-MRI should be interpreted only in combination with SSTR expression and morphologic changes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24526358      PMCID: PMC6336388          DOI: 10.1007/s11307-014-0722-7

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  36 in total

1.  Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients.

Authors:  Dow-Mu Koh; Erica Scurr; David Collins; Baris Kanber; Andrew Norman; Martin O Leach; Janet E Husband
Journal:  AJR Am J Roentgenol       Date:  2007-04       Impact factor: 3.959

2.  68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.

Authors:  A Kroiss; D Putzer; C Decristoforo; C Uprimny; B Warwitz; B Nilica; M Gabriel; D Kendler; D Waitz; G Widmann; I J Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-05       Impact factor: 9.236

Review 3.  Current knowledge on diagnosis and staging of neuroendocrine tumors.

Authors:  Kjell Oberg; Daniel Castellano
Journal:  Cancer Metastasis Rev       Date:  2011-03       Impact factor: 9.264

4.  Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy.

Authors:  Mary K G McStay; Dave Maudgil; Martin Williams; Jonathan M Tibballs; Anthony F Watkinson; Martyn E Caplin; John R Buscombe
Journal:  Radiology       Date:  2005-09-28       Impact factor: 11.105

5.  Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI.

Authors:  F L Giesel; C Kratochwil; A Mehndiratta; S Wulfert; J H Moltz; C M Zechmann; H U Kauczor; U Haberkorn; S Ley
Journal:  Eur J Radiol       Date:  2012-01-10       Impact factor: 3.528

Review 6.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

Review 7.  Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.

Authors:  W W de Herder; L J Hofland; A J van der Lely; S W J Lamberts
Journal:  Endocr Relat Cancer       Date:  2003-12       Impact factor: 5.678

8.  Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?

Authors:  Alejandro Forner; Carmen Ayuso; María Varela; Jordi Rimola; Amelia J Hessheimer; Carlos Rodriguez de Lope; María Reig; Luís Bianchi; Josep M Llovet; Jordi Bruix
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

Review 9.  Technology insight: water diffusion MRI--a potential new biomarker of response to cancer therapy.

Authors:  Daniel M Patterson; Anwar R Padhani; David J Collins
Journal:  Nat Clin Pract Oncol       Date:  2008-02-26

10.  Transarterial liver-directed therapies of neuroendocrine hepatic metastases.

Authors:  Javier Nazario; Sanjay Gupta
Journal:  Semin Oncol       Date:  2010-04       Impact factor: 4.929

View more
  10 in total

Review 1.  [Radionuclide therapy of endocrine-related cancer].

Authors:  C Kratochwil; F L Giesel
Journal:  Radiologe       Date:  2014-10       Impact factor: 0.635

Review 2.  Radiotherapy response evaluation using FDG PET-CT-established and emerging applications.

Authors:  Helen Cliffe; Chirag Patel; Robin Prestwich; Andrew Scarsbrook
Journal:  Br J Radiol       Date:  2017-01-30       Impact factor: 3.039

3.  Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors.

Authors:  Yogindra Vedvyas; Enda Shevlin; Marjan Zaman; Irene M Min; Alejandro Amor-Coarasa; Spencer Park; Susan Park; Keon-Woo Kwon; Turner Smith; Yonghua Luo; Dohyun Kim; Young Kim; Benedict Law; Richard Ting; John Babich; Moonsoo M Jin
Journal:  JCI Insight       Date:  2016-11-17

4.  Early Whole-Body Diffusion-weighted MRI Helps Predict Long-term Outcome Following Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumors.

Authors:  Vincent Vandecaveye; Raphaëla C Dresen; Elin Pauwels; Sofie Van Binnebeek; Ragna Vanslembrouck; Kristof Baete; Felix M Mottaghy; Paul M Clement; Kristiaan Nackaerts; Eric Van Cutsem; Chris Verslype; Frederik De Keyzer; Christophe M Deroose
Journal:  Radiol Imaging Cancer       Date:  2022-05

Review 5.  Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development.

Authors:  Rocio Garcia-Carbonero; Roberto Garcia-Figueiras; Alberto Carmona-Bayonas; Isabel Sevilla; Alex Teule; Maria Quindos; Enrique Grande; Jaume Capdevila; Javier Aller; Javier Arbizu; Paula Jimenez-Fonseca
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

Review 6.  A decade of multi-modality PET and MR imaging in abdominal oncology.

Authors:  Lisa A Min; Francesca Castagnoli; Wouter V Vogel; Jisk P Vellenga; Joost J M van Griethuysen; Max J Lahaye; Monique Maas; Regina G H Beets Tan; Doenja M J Lambregts
Journal:  Br J Radiol       Date:  2021-08-13       Impact factor: 3.629

Review 7.  Radiopharmaceutical Chemistry and Drug Development-What's Changed?

Authors:  Charles A Kunos; David A Mankoff; Michael K Schultz; Stephen A Graves; Daniel A Pryma
Journal:  Semin Radiat Oncol       Date:  2021-01       Impact factor: 5.934

Review 8.  Potentials and challenges of diffusion-weighted magnetic resonance imaging in radiotherapy.

Authors:  Sara Leibfarth; René M Winter; Heidi Lyng; Daniel Zips; Daniela Thorwarth
Journal:  Clin Transl Radiat Oncol       Date:  2018-09-20

9.  Development of Novel 111-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid Tumours.

Authors:  Benjamin Poret; Laurence Desrues; Marc-André Bonin; Martin Pédard; Martine Dubois; Richard Leduc; Romain Modzelewski; Pierre Decazes; Fabrice Morin; Pierre Vera; Hélène Castel; Pierre Bohn; Pierrick Gandolfo
Journal:  Biomolecules       Date:  2020-03-19

10.  Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI.

Authors:  Thomas Weikert; Ole Christopher Maas; Tanja Haas; Markus Klarhöfer; Jens Bremerich; Flavio Forrer; Alexander Walter Sauter; Gregor Sommer
Journal:  Contrast Media Mol Imaging       Date:  2019-11-11       Impact factor: 3.161

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.